Mednax Inc. (MD) Stake Reduced by Icon Advisers Inc. Co.
Icon Advisers Inc. Co. decreased its stake in Mednax Inc. (NYSE:MD) by 26.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 32,000 shares of the company’s stock after selling 11,800 shares during the period. Icon Advisers Inc. Co.’s holdings in Mednax were worth $2,120,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of MD. Nordea Investment Management AB raised its stake in shares of Mednax by 317.0% in the second quarter. Nordea Investment Management AB now owns 2,817,940 shares of the company’s stock worth $204,103,000 after buying an additional 2,142,237 shares during the period. Wedge Capital Management L L P NC bought a new stake in shares of Mednax during the second quarter worth about $109,915,000. Victory Capital Management Inc. raised its stake in shares of Mednax by 17,600.5% in the third quarter. Victory Capital Management Inc. now owns 1,443,301 shares of the company’s stock worth $95,619,000 after buying an additional 1,435,147 shares during the period. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Mednax during the second quarter worth about $80,335,000. Finally, Bank of Montreal Can bought a new stake in shares of Mednax during the second quarter worth about $34,026,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.
Mednax Inc. (NYSE:MD) traded up 1.04% on Tuesday, reaching $66.01. 479,673 shares of the company’s stock were exchanged. Mednax Inc. has a 12 month low of $59.36 and a 12 month high of $76.96. The firm has a market cap of $6.11 billion, a PE ratio of 18.13 and a beta of 0.62. The firm’s 50-day moving average is $63.96 and its 200-day moving average is $67.35.
Mednax (NYSE:MD) last issued its earnings results on Thursday, October 27th. The company reported $1.09 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.11 by $0.02. Mednax had a net margin of 10.97% and a return on equity of 14.47%. The firm earned $828 million during the quarter, compared to the consensus estimate of $821.18 million. During the same period in the previous year, the company posted $1.10 EPS. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, equities analysts forecast that Mednax Inc. will post $4.04 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at http://www.financial-market-news.com/mednax-inc-md-stake-reduced-by-icon-advisers-inc-co/1209293/.
A number of equities research analysts have issued reports on MD shares. Jefferies Group decreased their target price on shares of Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, August 26th. Zacks Investment Research lowered shares of Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, October 19th. Mizuho reissued a “buy” rating and set a $79.00 target price on shares of Mednax in a research note on Tuesday, September 20th. Raymond James Financial Inc. lowered shares of Mednax from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 27th. Finally, Citigroup Inc. decreased their target price on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 17th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $74.44.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total value of $97,515.00. Following the completion of the sale, the director now owns 12,755 shares of the company’s stock, valued at $829,202.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by company insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax Inc. (NYSE:MD).
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.